Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H15ClN4O2 |
| Molecular Weight | 390.822 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C(C=C1)[C@@]23N(CCN2C(=O)C4=C3C=NC=C4)C(=O)C5=CN=CC=C5
InChI
InChIKey=QZSZPSDRJPPZDZ-OAQYLSRUSA-N
InChI=1S/C21H15ClN4O2/c22-16-5-3-15(4-6-16)21-18-13-24-9-7-17(18)20(28)26(21)11-10-25(21)19(27)14-2-1-8-23-12-14/h1-9,12-13H,10-11H2/t21-/m1/s1
| Molecular Formula | C21H15ClN4O2 |
| Molecular Weight | 390.822 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:10:21 GMT 2023
by
admin
on
Sat Dec 16 12:10:21 GMT 2023
|
| Record UNII |
9VR1J6U4XG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9VR1J6U4XG
Created by
admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL2109567
Created by
admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
|
PRIMARY | |||
|
BTA-9881
Created by
admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
|
PRIMARY | BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.BTA9881 is a small molecule fusion glycoprotein inhibitor, designed to specifically inhibit the process by which respiratory syncytial virus (RSV) infects a cell.BTA9881 will be used to stop replication of RSV in an infected patient with the aim of clearing the infection or reducing the clinical impact of the disease. Respiratory syncytial virus (RSV) infects people of all ages, but particularly infants, causing similar symptoms to influenza. In the northern hemisphere, the RSV season usually starts in the fall and runs through the spring. The virus is highly contagious, infecting virtually all infants under the age of two and re-infection is common. For example approximately 50 percent of children will experience two RSV infections by the age of two. | ||
|
1646857-24-0
Created by
admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
|
PRIMARY | |||
|
70807574
Created by
admin on Sat Dec 16 12:10:21 GMT 2023 , Edited by admin on Sat Dec 16 12:10:21 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Biota Holdings; Class: Antiviral, Small molecule; Mechanism of Action: Viral fusion protein inhibitor; Highest Development Phase: Discontinued for Respiratory syncytial virus infections; Most Recent Events: 31 Aug 2009 BTA 9881 is no longer licensed to MedImmune/AstraZeneca, 16 Jul 2007 Phase-I clinical trials in Respiratory syncytial virus infections in Australia (PO)
|
